Compare ALCO & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | TNYA |
|---|---|---|
| Founded | 1960 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.7M | 234.8M |
| IPO Year | N/A | 2021 |
| Metric | ALCO | TNYA |
|---|---|---|
| Price | $36.52 | $1.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 26.5K | ★ 2.0M |
| Earning Date | 11-24-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,066,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.76 | $0.36 |
| 52 Week High | $37.50 | $4.01 |
| Indicator | ALCO | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 61.04 | 52.21 |
| Support Level | $31.42 | $1.34 |
| Resistance Level | $37.50 | $1.43 |
| Average True Range (ATR) | 0.91 | 0.10 |
| MACD | 0.40 | 0.03 |
| Stochastic Oscillator | 77.35 | 86.67 |
Alico Inc is a Florida-based agribusiness and land management company that primarily focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells primarily Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers most of the revenue as the firm's primary operating business unit.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.